The Venture Codex Logo

The Venture Codex

Overview

CRISPR-engineered precision antibacterial platform for bacterial diseases.

Total Raised

$87 M

Rounds

5

Links

Verticals

Biopharma
Biotechnology
Therapeutics

Investment History

  1. Series B

    May 2022

    $35M

  2. Debt Financing

    Oct 2021

    $25M

  3. Series A

    Nov 2017

    $19M

  4. Convertible Note

    Jul 2017

    $5M

Team

Paul Garofolo

Co-Founder, Chief Executive Officer, & Chairman of the Board

Charles Gersbach

Co-Founder & Scientific Advisor

Chase Beisel

Co-Founder & Scientific Advisor

Nick Conley

Vice President of Technology, Pharmaceutical Operations and Technology